Adjusting Antiretroviral Therapy Dosage Using Therapeutic Drug Monitoring (TDM)
Human Immunodeficiency Virus, HIV Infections
About this trial
This is an interventional treatment trial for Human Immunodeficiency Virus focused on measuring HIV, Adjusting Antiretroviral Therapy, Dosage using Therapeutic Drug Monitoring, Swiss HIV Cohort Study, HIV Geneva, lopinavir, efavirenz, Treatment Experienced
Eligibility Criteria
Inclusion Criteria:
- Stable regimen including either EFV or LPV/r
- HIVRNA below 40 copies since at least 3 months
- Antiretroviral drug concentration (EFV, LPV/r) plasma concentration at screening above P75
- Signed consent for the SHCS genetics core project
Exclusion Criteria:
- Concomitant medication:Amiodarone, bepidril, flecainide, propafenone, quinidine,Astemizole, terfenadine,Dihydroergotamine, ergotamine,Midazolam, triazolam,Cisapride,Pimozide,Rifabutin
- Renal or hepatic impairment
- Pregnancy or wish to become pregnant within the next 6 months
- Both EFV and LPV/r as part of the antiretroviral drug regimen
Sites / Locations
- University Hopistal of GenevaRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
LPV
EFV
Patients with blood levels measured 2 times at 2 weeks intervals in the upper quartile (>percentile 75) of concentrations reported under standard therapy (i.e. EFV 600 mg q.d. or LPV/r 400 or 533 mg bid) will have their dose reduced by approximately one third, with the aim to bring their concentration in the 25-75% percentile range.
Patients with blood levels measured 2 times at 2 weeks intervals in the upper quartile (>percentile 75) of concentrations reported under standard therapy (i.e. EFV 600 mg q.d. or LPV/r 400 or 533 mg bid) will have their dose reduced by approximately one third, with the aim to bring their concentration in the 25-75% percentile range.